#204 - Centenarians, metformin, and longevity | Nir Barzilai, M.D.

Episode Summary

Executive Summary: Peter Attia and Nir Barzilai explore what centenarians reveal about longevity genetics, emphasizing that exceptional lifespan is driven less by perfect health behaviors or absence of bad genes and more by protective, polygenic resilience pathways. They then dive deeply into metformin, discussing TAME, human and animal evidence, exercise interactions, biomarkers, and why aging trials need composite outcomes and better mechanistic readouts.

Main Topics: Centenarians as a model of healthy aging (Priority: 5/5): Barzilai explains that centenarians are not simply people with ideal lifestyles or flawless genomes; they often carry disease-risk variants yet still reach extreme ages, suggesting protective longevity biology and delayed disease onset. Longevity genes and protective pathways (Priority: 5/5): The discussion covers APOE2, CETP, GHR/IGF-1, FOXO3A, TSHR, LPA, and Klotho, with emphasis on polygenic resilience, antagonistic pleiotropy, and pathway-level biology rather than single-gene explanations. Healthspan vs lifespan and compression of morbidity (Priority: 5/5): They debate whether centenarians truly have better healthspan or simply get sick later, concluding that the key pattern is delayed onset of chronic disease and a shorter terminal period of morbidity. Metformin as a gerotherapeutic and the TAME trial (Priority: 5/5): Barzilai outlines metformin’s history, safety, observational and clinical evidence, and the design logic of TAME as a composite-outcome trial intended to secure an FDA aging indication. Metformin, exercise, and muscle/mitochondrial trade-offs (Priority: 4/5): They discuss evidence that metformin may blunt cardiorespiratory fitness and alter muscle signaling, while also potentially improving some transcriptomic markers; the effects appear context- and person-dependent. Biomarkers of aging and the limits of epigenetic clocks (Priority: 4/5): Both speakers are skeptical of current biological clocks as individual-level decision tools, favoring biomarkers that are mechanistic, longitudinal, and responsive to treatment, such as proteomics and pathway-based measures. NAD precursors and other popular longevity interventions (Priority: 3/5): Barzilai expresses uncertainty about NR/NMN and other supplements, arguing that the biology is not yet convincing enough to support strong claims of geroprotection.

Key Arguments: Centenarians are not defined by perfect behavior; many smoke, are overweight, and do not exercise, so lifestyle alone cannot explain exceptional longevity. The absence of disease-causing variants is not enough to explain centenarian status; many centenarians still carry high-risk genotypes such as APOE4 homozygosity. Longevity appears to involve protective genotypes and pathways, especially insulin/IGF-1, mTOR, MAPK, CETP, APOE2, and FOXO3A-related biology. Low IGF-1 and altered growth hormone signaling can be beneficial later in life, but the same pathway may be advantageous when young and harmful when old, consistent with antagonistic pleiotropy. Centenarians often show delayed disease onset by 20-30 years and a compressed period of morbidity rather than complete avoidance of disease. Metformin has enough human observational and clinical signal to justify TAME, but existing studies are confounded and do not yet prove geroprotection in humans. TAME is designed as a composite aging trial because a single disease endpoint would be too narrow and could force early stopping if one disease signal emerges. Metformin may have trade-offs with exercise adaptation, especially cardiorespiratory fitness and muscle signaling, so its value may depend on biological age and activity level. Current epigenetic clocks are not sufficiently mechanistic or stable for individual treatment decisions; better biomarkers should reflect biology and change with intervention. NAD precursor biology remains uncertain; without clear mechanistic and measurable evidence, enthusiasm should remain cautious.

Data Points: Centenarian cohort size: 500+ healthy elderly people aged 95-112 and their offspring - Barzilai’s Longevity Genes Project description Centenarian study size: 750 centenarians - Barzilai notes the current Ashkenazi Jewish centenarian cohort APOE4 homozygotes among centenarians: 2 centenarians - Examples of individuals expected to have dementia/death much earlier but who reached 100 without dementia CETP/APOC3 homozygosity in centenarians: ~20% in centenarians vs ~8-9% in controls - Early longevity-genotype findings in lipid metabolism GHR exon 3 deletion homozygosity: 12% in centenarians vs 3% in controls - Growth hormone receptor variant associated with lower IGF-1 and longevity phenotype IGF-1 effect in older adults: Lowest half of IGF-1 lived twice as long as highest half - Female centenarians; lower IGF-1 predicted longer survival Female centenarian ratio: 85 females for every 15 males - Global sex distribution among centenarians High TSH in centenarians: TSH around 5-8 - Despite normal free T4 and free T3, suggesting a mild hypothyroid-like state may be physiologic in old age DPP diabetes prevention effect: ~30% prevention with metformin and ~30% with lifestyle - NIH Diabetes Prevention Program Metformin side effects: 3-5% (or more in elderly) have persistent diarrhea - Most adverse effects occur early and are GI-related Metformin in animal studies: ~7-10% average lifespan effect across studies - Barzilai’s summary of animal longevity data ITP metformin result: 0.1% dose produced ~4% longer life; 1% dose was toxic - Discussed as a reason animal results may depend heavily on dose TAME age range: 65-79 years - Planned enrollment age for the metformin aging trial TAME sample size: ~3,500 participants - Current target size discussed for the trial TAME budget: ~$50 million - Bare-bones budget estimate for the trial Metformin and lactate: Lactate rose from below 1 to above 1 in every patient in Barzilai’s 1987 study - Used as a biomarker of metformin exposure/compliance Metformin and GDF-15: ~3.5-fold increase - Mentioned as another biomarker that rises with metformin use Centenarian morbidity cost: Last 2 years of life cost one-third as much as people dying at 70 - CDC data cited to support compression of morbidity Offspring biomarker comparison: Offspring of exceptional longevity parents had about half the biomarkers of controls - Interpreted as being younger biologically, with later emergence of aging markers

Pivotal Quotes: "If we understand this 20%, understand it really, we can use that in order to prevent the 80% of the environment." — Nir Barzilai: On the value of studying genetic contribution to lifespan despite environmental influence "The lesson from centenarians is that there are longevity genes that could be translated into drugs." — Nir Barzilai: Summarizing the translational takeaway from centenarian research "I think you shouldn't get senolytics before you're 70 or 80 years old." — Nir Barzilai: On timing geroprotective interventions and the risk of antagonistic pleiotropy

Implications: The episode argues for a shift from single-disease thinking to pathway-based aging medicine, with centenarian genetics guiding drug discovery and TAME potentially legitimizing aging as a therapeutic target. It also warns that popular interventions like metformin, growth hormone, and NAD precursors may be highly context-dependent and need better biomarkers and trials.